Indaptus Therapeutics Q3 net loss narrows as R&D costs fall
Overview
US biotechnology firm's Q3 net loss narrowed sharply from prior year
Research and development expenses fell 82% due to lower clinical costs and reduced headcount
Company completed $24 mln private placement to fund research and working capital
Outlook
Company intends to use recent funding for R&D and early-stage neurotechnology device research
Indaptus expects current liquidity to fund anticipated operating and capital expenditures
Result Drivers
R&D COST CUTS - Research and development expenses fell sharply due to lower clinical costs from Decoy20 Phase 1 study wind-down and reduced headcount
ADMINISTRATIVE SAVINGS - General and administrative expenses declined due to lower management transition costs and payroll reductions
LIQUIDITY - As of September 30, the company had $26.6 million in cash and cash equivalents and $4.0 million in short-term investments
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss Per Share | $0.01 |
Reuters Recommended Reads
Nov 12 - MDxHealth's Q3 revenue misses expectations due to disrupted commercial execution
Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)